3M Company, acting as the selling shareholder, announced the pricing of a secondary offering of 8,800,000 shares of Solventum Corporation's common stock. This transaction is expected to result in gross proceeds of approximately $648 million for 3M.
All of the shares of common stock in this offering are being sold by 3M, meaning Solventum Corporation will not receive any of the proceeds. This move is part of 3M's ongoing strategy to monetize its remaining stake in the healthcare business that was spun off.
The offering is expected to close on August 14, 2025. This divestiture contributes to 3M's capital deployment strategy and provides additional financial flexibility following the separation of Solventum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.